Effects of probiotic PCC® on atopic dermatitis

Weston, et al. Effects of probiotics on atopic dermatitis: a randomised controlled trial. Archives of Diseases in Childhood. 2005;90:892-897

The study investigated the effects of PCC® on moderate and severe atopic dermatitis (eczema) in infants aged 6-18 months. The study was conducted in Western Australia at the Institute for Child Health as a randomised, double blind, placebo controlled clinical trial. 53 children completed the study. The children were divided into two groups and given either PCC® (1 billion CFU) or a placebo for eight weeks.

General findings

The severity and extent of eczema symptoms was assessed using the SCORAD index at baseline and at eight and 16 weeks. A significant reduction in eczema symptoms was seen in the PCC® group but not in the placebo group. Furthermore, this improvement continued for at least eight weeks after dosing was completed.


The authors concluded that “supplementation with PCC® is beneficial in improving the extent and severity of atopic dermatitis in young children with moderate or severe disease”. As a secondary benefit, the study also showed that significantly fewer infants who were given PCC® had lower respiratory tract infections compared to the placebo group.

Read a summary of the study and its findings

Supplier Member

Bioxyne Ltd.

Suite 506, Level 5
50 Clarence St
Sydney, NSW 2000, Australia

P: +61 2 9078 8180
E: info@bioxyne.com
ABN: 97 084 464 193


Sign Up